Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hallenbeck, US
Chris Hallenbeck, Palo Alto, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120004769 | AUTOMATED RETAIL SHELF UNITS AND SYSTEMS - Provided are automated retail shelf (ARS) units and corresponding network systems for facilitating retail of various product items in retail environments. An ARS unit includes a chassis sized and configured for attaching to a retail shelf unit and being supported by the shelf unit at an elevated level convenient for customer interactions. The ARS unit may be positioned in a retail aisle among other product items, for example, unsecured product items. The ARS unit provides secure storage to specific product items available for sale from the unit. These product items may have high values and be more susceptible to theft unlike other unsecured product items available from retail shelves. The ARS unit may be used to provide information about product items stored in the unit and, in certain embodiments, unsecured product items available from retail shelves, such as indicating location of these items in the retail environment. | 01-05-2012 |
Donald Hallenbeck, West Lafayette, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20100092576 | PHARMACEUTICAL COMPOSITIONS CONTAINING LANTHANUM HYDROXYCARBONATE - An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement. | 04-15-2010 |
Jeremey Hallenbeck, Highland, NY US
John M. Hallenbeck, Kensington, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080234196 | Treatment and prevention of vascular dementia - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 09-25-2008 |
| 20100204096 | TREATMENT OF INFLAMMATION, DEMYELINATION AND NEURONAL/AXONAL LOSS - The invention relates to compositions and methods for treating or preventing inflammation in a mammal comprising mucosal administration of an effective amount of an E-selectin polypeptide. Such compositions and methods are useful for treating or preventing a variety of conditions and diseases, including, for example, stroke, vascular dementia and autoimmune or inflammatory demyelinating diseases such as multiple sclerosis. | 08-12-2010 |
| 20110053843 | E-SELECTIN COMPOSITIONS AND USE THEREOF FOR INDUCING E-SELECTIN TOLERANCE - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 03-03-2011 |
John R. Hallenbeck, Tucson, AZ US
| Patent application number | Description | Published |
|---|---|---|
| 20090120414 | INTERNAL COMBUSTION ENGINE USING COMBUSTIBLE GASES PRODUCED BY THE ELECTROLYSIS OF WATER, AND VEHICLE COMPRISING SAME - An engine system comprising an electrolysis apparatus interconnected to an internal combustion engine. The electrolysis apparatus cleaves water into a mixture of hydrogen gas and oxygen gas. The mixture of hydrogen gas and oxygen gas is input into, and fuels, the internal combustion engine. A vehicle comprising the engine system. | 05-14-2009 |
Paul Hallenbeck, Gaithersburg, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090098599 | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use - The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits. | 04-16-2009 |
Paul L. Hallenbeck, Gaithersburg, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080213884 | Vectors for tissue-specific replication - The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated. | 09-04-2008 |
Paul L. Hallenbeck, Chester Springs, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100129325 | SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms. | 05-27-2010 |